Clinical practice guidelines for the diagnosis and treatment of inflammatory breast cancer 2022.V1(CSBrS-Guideline-21)

Title: Clinical practice guidelines for the diagnosis and treatment of inflammatory breast cancer 2022.V1(CSBrS-Guideline-21)
Edition: Original
Classification: Experts consensus
Field: Diagnosis and Treatment
Countries and regions: China
Guidelines users: Chinese breast diseases specialists and related medical workers
Evidence classification method: None
Development unit: 中华医学会外科学分会乳腺外科学组
Registration time: 2022-01-23
Registration number: IPGRP-2022CN046
Purpose of the guideline: In order to improve the clinical diagnosis and treatment of inflammatory breast cancer (IBC), the Chinese Medical Association Surgery Branch organized experts to put forward key clinical issues related to the clinical practice of IBC through literature research and discussion. Development and Evaluation) system to evaluate relevant evidence, and combined with clinical accessibility in China, the Chinese Medical Association IBC clinical practice guidelines are formulated, aiming to provide reference for Chinese breast cancer and other professional physicians.